ClinicalTrials.gg
CompletedNCT06181435Updated Aug 13, 2026

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

A Phase 3 interventional study of Amlitelimab and Placebo in Dermatitis Atopic, sponsored by Sanofi. Completed at 142 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
589
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing amlitelimab in Dermatitis, Atopic — none open to participants now, 4 under way, 3 of them phase 3. amlitelimab · Dermatitis, Atopic.

Enrollment
6th of 11
589 · median 589
Started
2023
with 3 others
Phase 3
5 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
9 of 11
Sanofi

Among the 11 studies testing amlitelimab in Dermatitis, Atopic, this one is the 6th largest by enrollment, is one of 4 that started in 2023, is one of 5 in phase 3, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 11 studies testing amlitelimab in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About amlitelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing amlitelimab in Dermatitis, Atopic as a file.
02

Study summary

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older.

Study details include:

At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY).

For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up.

For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period.

The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 12 years of age (when signing form)
  • Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)
  • Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments, and/or inadequate response to systemic therapies (within 12 months before screening)
  • v-IGA-AD of 3 or 4 at baseline visit
  • EASI score of 16 or higher at baseline
  • AD involvement of 10% or more of BSA at baseline
  • Weekly average of daily PP-NRS of ≥ 4 at baseline visit.
  • Able and willing to comply with requested study visits and procedures
  • Body weight ≥ 25 kg

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Skin co-morbidity that would adversely affect the ability to undertake AD assessments
  • Known history of or suspected significant current
  • Any or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured >5 years prior to baseline)
  • History of solid organ or stem cell transplant
  • Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline
  • Positive for (HIV), or at screening visit
  • Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB
  • Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
  • In the Investigator's opinion, any laboratory results or protocol specified laboratory abnormalities at screening
  • History of or allergy to any of the or medicinal product (IMP)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
589 participants (actual)

Study arms

  • Experimental
    Amlitelimab dose 1

    Subcutaneous injection as per protocol

    Drug: Amlitelimab

  • Experimental
    Amlitelimab dose 2

    Subcutaneous injection as per protocol

    Drug: Amlitelimab

  • Placebo comparator
    Placebo

    Subcutaneous injection as per protocol

    Drug: Placebo

Interventions

  • Pharmaceutical form: Injection solution Route of administration: SC injection

    Also known as: SAR445229

  • DrugPlacebo

    Pharmaceutical form: Injection solution Route of administration: SC injection

06

What researchers measure

Primary outcomes

  1. EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Week 24

  2. EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Week 24

  3. US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Week 24

Secondary outcomes

  1. Proportion of participants reaching EASI-75 at Week 24 (for US and US reference countries only)

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.

    Time frame: Week 24

  2. Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting) and a reduction from baseline of ≥2 points

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Baseline to Week 24

  3. Proportion of participants with ≥4-point reduction in weekly average of daily Peak Pruritus-Numerical Rating Scale (PP-NRS) from baseline in participants with baseline weekly average of daily PP-NRS ≥4

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to Week 24

  4. Proportion of participants reaching EASI-75

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.

    Time frame: Baseline to Week 20

  5. Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Baseline to Week 20

  6. Proportion of participants with vIGA-AD 0 (clear)

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Week 24

  7. Proportion of participants reaching EASI-90

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.

    Time frame: Baseline to Week 24

  8. Proportion of participants reaching EASI-100

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.

    Time frame: Baseline to Week 24

  9. Proportion of participants with PP-NRS 0 or 1

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to Week 24

  10. Change in Dermatology Life Quality Index (DLQI) from baseline in participants with age ≥16 years old

    The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Baseline to Week 24

  11. Proportion of participants with a reduction in DLQI ≥4 from baseline in participants with age ≥16 years old and with DLQI baseline ≥4

    The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Baseline to Week 24

  12. Change in Children Dermatology Life Quality Index (CDLQI) from baseline in participants with age ≥12 to <16 years old

    The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Baseline to Week 24

  13. Proportion of participants with a reduction in CDLQI ≥6 from baseline in participants with age ≥12 to <16 years old and with CDLQI baseline ≥6

    The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL

    Time frame: Baseline to Week 24

  14. Change in Hospital Anxiety Depression Scale (HADS) from baseline

    The HADS is 14-item questionnaire with two subscales: anxiety \& depression. Each subscale (anxiety \& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.

    Time frame: Baseline to Week 24

  15. Proportion of participants with HADS subscale Anxiety (HADS-A) <8 in participants with baseline HADS-A ≥8

    HADS-A score ranges 0-21 with higher score indicating a poorer state.

    Time frame: Baseline to Week 24

  16. Proportion of participants with HADS subscale Depression (HADS-D) <8 in participants with HADS-D baseline ≥8

    HADS-D score ranges 0-21 with higher score indicating a poorer state.

    Time frame: Baseline to Week 24

  17. Absolute change in weekly average of daily Skin Pain-Numerical Rating Scale (SP-NRS) from baseline

    The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.

    Time frame: Baseline to Week 24

  18. Proportion of participants with a reduction in weekly average of daily SP-NRS ≥4 from baseline in participants with baseline weekly average of daily SP-NRS ≥4

    The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.

    Time frame: Baseline to Week 24

  19. Absolute change in weekly average of daily Sleep Disturbance-Numerical Rating Scale (SD-NRS) from baseline

    The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.

    Time frame: Baseline to Week 24

  20. Proportion of participants with a reduction in weekly average of daily SD-NRS ≥3 from baseline in participants with Baseline weekly average of daily SD-NRS ≥3

    The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.

    Time frame: Baseline to Week 24

  21. Percent change in weekly average of daily SP-NRS from baseline

    The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.

    Time frame: Baseline to Week 24

  22. Percent change in weekly average of daily SD-NRS from baseline

    The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.

    Time frame: Baseline to Week 24

  23. Percent change in EASI score from baseline

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Baseline to Week 24

  24. Percent change in weekly average of daily PP-NRS from baseline

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to Week 24

  25. Absolute change in weekly average of daily PP-NRS from baseline

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Baseline to Week 24

  26. Proportion of participants reaching EASI-50

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.

    Time frame: Baseline to Week 24

  27. Proportion of participants with EASI ≤7

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Baseline to Week 24

  28. Change in percent Body Surface Area (BSA) affected by AD from baseline

    Time frame: Baseline to Week 24

  29. Percent change in Scoring Atopic Dermatitis (SCORAD) index from baseline

    The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 24

  30. Absolute change in SCORAD index from baseline

    The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 24

  31. Proportion of participants with a reduction in SCORAD ≥ 8.7 points from baseline in participants with baseline SCORAD score ≥ 8.7

    The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 24

  32. Change in Patient Oriented Eczema Measure (POEM) from baseline

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.

    Time frame: Baseline to Week 24

  33. Proportion of participants with a reduction in POEM ≥4 from baseline in participants with POEM Baseline ≥4

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.

    Time frame: Baseline to Week 24

  34. Proportion of participants with rescue medication use

    Time frame: Baseline to Week 24

  35. Percentage of participants who experience Treatment-Emergent Adverse Events (TEAEs), experience Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment- Emergent Adverse Events of Special Interest (AESI)

    Time frame: Baseline to Week 40

  36. Serum amlitelimab concentrations

    Time frame: Baseline to Week 40

  37. Incidence of antidrug antibodies (ADAs) of amlitelimab

    Time frame: Baseline to Week 40

07

Study locations

142 sites
  • Center for Dermatology and Plastic Surgery- Site Number : 8401119
    Scottsdale, Arizona 85260, United States
  • Eclipse Clinical Research- Site Number : 8401158
    Tucson, Arizona 85745, United States
  • Torrance Clinical Research- Site Number : 8401027
    Lomita, California 90717, United States
  • Dermatology Research Associates - Los Angeles- Site Number : 8401092
    Los Angeles, California 90045, United States
  • Allergy & Asthma Associates of Southern California - Mission Viejo- Site Number : 8401079
    Mission Viejo, California 92691, United States
  • Cura Clinical Research - Oxnard- Site Number : 8401142
    Oxnard, California 93030, United States
  • Clinical Science Institute- Site Number : 8401028
    Santa Monica, California 90404, United States
  • University of Connecticut Health Center- Site Number : 8401115
    Farmington, Connecticut 06032, United States
  • Pediatric Skin Research- Site Number : 8401198
    Coral Gables, Florida 33146, United States
  • Skin Care Research - Hollywood- Site Number : 8401071
    Hollywood, Florida 33021, United States
  • Savin Medical Group - Miami- Site Number : 8401085
    Miami, Florida 33126, United States
  • Anchor Medical Research- Site Number : 8401300
    Miami, Florida 33176, United States
  • Accel Research - Nona Pediatric Center- Site Number : 8401081
    Orlando, Florida 32829, United States
  • Nuline Clinical Trial Center- Site Number : 8401161
    Pompano Beach, Florida 33060, United States
  • Clinical Research Trials of Florida- Site Number : 8401023
    Tampa, Florida 33607, United States
  • AllerVie Clinical Research - Columbus- Site Number : 8401104
    Columbus, Georgia 31904, United States
  • First Georgia Physician Group- Site Number : 8401190
    Fayetteville, Georgia 30214, United States
  • Access Dermatology- Site Number : 8401296
    Bowling Green, Kentucky 42104, United States
  • MedPharmics - Covington- Site Number : 8401137
    Covington, Louisiana 70433, United States
  • Care Access Research - Marriottsville- Site Number : 8401126
    Marriottsville, Maryland 21104, United States
  • Tufts Medical Center Site Number : 8401201
    Boston, Massachusetts 02111, United States
  • University Of Mississippi Medical Center- Site Number : 8401184
    Jackson, Mississippi 39216, United States
  • Care Access - Hoboken- Site Number : 8401132
    Hoboken, New Jersey 07030, United States
  • University of New Mexico Comprehensive Cancer Center- Site Number : 8401263
    Albuquerque, New Mexico 87102, United States
  • OmeraNY- Site Number : 8401156
    Brooklyn, New York 11220, United States
  • Equity Medical- Site Number : 8401239
    New York, New York 10023, United States
  • Montefiore Medical Center - Moses Campus- Site Number : 8401150
    The Bronx, New York 10467, United States
  • Red River Research Partners- Site Number : 8401196
    Fargo, North Dakota 58103, United States
  • Bexley Dermatology Research- Site Number : 8401051
    Bexley, Ohio 43209, United States
  • Velocity Clinical Research - Springdale- Site Number : 8401153
    Cincinnati, Ohio 45246, United States
  • Dermatology Associates of Plymouth Meeting- Site Number : 8401147
    Plymouth Meeting, Pennsylvania 19462, United States
  • PEAK Research- Site Number : 8401083
    Upper Saint Clair, Pennsylvania 15241, United States
  • Columbia Dermatology & Aesthetics- Site Number : 8401166
    Columbia, South Carolina 29212, United States
  • Health Concepts- Site Number : 8401059
    Rapid City, South Dakota 57702, United States
  • Arlington Research Center- Site Number : 8401248
    Arlington, Texas 76011, United States
  • Derm Texas- Site Number : 8401217
    Dallas, Texas 75235, United States
  • Center for Clinical Studies - Houston - Binz Street- Site Number : 8401063
    Houston, Texas 77004, United States
  • Prolato Clinical Research Center- Site Number : 8401209
    Houston, Texas 77054, United States
  • Sienna Dermatology- Site Number : 8401148
    Missouri City, Texas 77459, United States
  • Progressive Clinical Research - San Antonio- Site Number : 8401016
    San Antonio, Texas 78229, United States
  • Advanced Research Institute - Odgen- Site Number : 8401057
    Ogden, Utah 84405, United States
  • Care Access - Arlington- Site Number : 8401134
    Arlington, Virginia 22206, United States
  • Velocity Clinical Research - Hampton- Site Number : 8401154
    Hampton, Virginia 23666, United States
  • Investigational Site Number : 0320021
    Berazategui, Buenos Aires 1886, Argentina
  • Investigational Site Number : 0320017
    Pilar, Buenos Aires 1629, Argentina
  • Investigational Site Number : 0320006
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320007
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320015
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320016
    Buenos Aires, 1055, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320009
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 1002008
    Gabrovo, 5300, Bulgaria
  • Investigational Site Number : 1002004
    Pleven, 5800, Bulgaria
  • Investigational Site Number : 1002005
    Sofia, 1431, Bulgaria
  • Investigational Site Number : 1520004
    Valdivia, Los Ríos Region 5110683, Chile
  • Investigational Site Number : 1520013
    Santiago, Reg Metropolitana de Santiago 7500505, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number : 1520014
    Santiago, Reg Metropolitana de Santiago 7750495, Chile
  • Investigational Site Number : 1520015
    Quillota, Valparaiso 2260877, Chile
  • Investigational Site Number : 1560004
    Beijing, 100191, China
  • Investigational Site Number : 1560030
    Beijing, 100730, China
  • Investigational Site Number : 1560022
    Chengdu, 610041, China
  • Investigational Site Number : 1560021
    Guangzhou, 510018, China
  • Investigational Site Number : 1560025
    Guangzhou, 510080, China
  • Investigational Site Number : 1560002
    Hangzhou, 310006, China
  • Investigational Site Number : 1560006
    Hangzhou, 310009, China
  • Investigational Site Number : 1560029
    Hangzhou, 310014, China
  • Investigational Site Number : 1560007
    Jinan, 250013, China
  • Investigational Site Number : 1560024
    Ningbo, 315010, China
  • Investigational Site Number : 1560001
    Shanghai, 200040, China
  • Investigational Site Number : 1560005
    Shanghai, 200443, China
  • Investigational Site Number : 1560026
    Shenyang, 110179, China
  • Investigational Site Number : 1560023
    Wenzhou, 325035, China
  • Investigational Site Number : 1560003
    Wuxi, 214000, China
  • Investigational Site Number : 1560028
    Zhenjiang, 212000, China
  • Investigational Site Number : 2032106
    Kutná Hora, 284 01, Czechia
  • Investigational Site Number : 2030010
    Olomouc, 779 00, Czechia
  • Investigational Site Number : 2032104
    Ostrava, 702 00, Czechia
  • Investigational Site Number : 2030011
    Prague, 150 00, Czechia
  • Investigational Site Number : 2030006
    Prague, 160 00, Czechia
  • Investigational Site Number : 2080002
    Aalborg, 9000, Denmark
  • Investigational Site Number : 2080001
    Aarhus, 8200, Denmark
  • Investigational Site Number : 2080003
    Herlev, 2730, Denmark
  • Investigational Site Number : 3800018
    Rozzano, Milano 20089, Italy
  • Investigational Site Number : 3800013
    Rome, Roma 00133, Italy
  • Investigational Site Number : 3800009
    Catania, 95123, Italy
  • Investigational Site Number : 3800008
    Pisa, 56126, Italy
  • Investigational Site Number : 3800022
    Vicenza, 36100, Italy
  • Investigational Site Number : 3920009
    Chitose, Hokkaido 066-0021, Japan
  • Investigational Site Number : 3923114
    Obihiro, Hokkaido 080-0013, Japan
  • Investigational Site Number : 3920008
    Sapporo, Hokkaido 064-0921, Japan
  • Investigational Site Number : 3920006
    Kobe, Hyōgo 653-0836, Japan
  • Investigational Site Number : 3920005
    Sagamihara, Kanagawa 252-0315, Japan
  • Investigational Site Number : 3923113
    Yokohama, Kanagawa 221-0825, Japan
  • Investigational Site Number : 3920010
    Miyagi-gun, Miyagi 981-0112, Japan
  • Investigational Site Number : 3920011
    Sendai, Miyagi 981-3133, Japan
  • Investigational Site Number : 3923109
    Habikino, Osaka 583-8588, Japan
  • Investigational Site Number : 3923110
    Sakai, Osaka 593-8324, Japan
  • Investigational Site Number : 3920002
    Iruma, Saitama 350-0495, Japan

Showing the first 100 of 142 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Nov 2025, 23 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 23 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 26, 2023
StartActual
Dec 21, 2023
Primary completionActual
Nov 25, 2025
CompletionActual
Mar 12, 2026
Results delay requested
Aug 11, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06181435
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Dec 21, 2023
Primary completion
Nov 25, 2025
Completion
Mar 12, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion